SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is experiencing significant volatility and social media debate as investors navigate a recent treasury exploit that sparked concerns about security and future token value. While some community members advocate for holding or accumulating during dips, others remain deeply skeptical and are calling it a failed project, highlighting a sharp divide between those betting on a recovery and those warning of a long-term decline.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is experiencing intense volatility as investors weigh the company's strong long-term AI infrastructure backlog against a broader sector-wide correction that has aggressively compressed valuations. While some market participants are expressing frustration over the recent sell-off, the active community remains deeply divided between those viewing the pullback as a prime accumulation opportunity for long-term growth and those bracing for further downside volatility.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is surging on heavy trading volume as investors speculate on potential institutional accumulation or news ahead of upcoming earnings. The community is buzzing over the stock reclaiming the five-dollar level, with many viewing it as a critical threshold for institutional eligibility and a catalyst for a potential short squeeze.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as retail investors engage in a heated debate over its persistent price weakness despite strong fundamental growth, with many venting frustration over institutional manipulation and dilution. Meanwhile, some traders are actively positioning for a potential pre-earnings run, focusing on the stock's consolidation near key technical support levels ahead of its upcoming quarterly release.

General Fusion Group Ltd. engages in the fusion industry, developing practical magnetized target fusion technology that is designed to address the key barriers to commercializing fusion. The company is headquartered in Richmond, Canada.

General Fusion Group Ltd.

General Fusion is capturing market attention as it transitions into the public markets via a business combination, sparking active debate among community members regarding its fusion technology milestones compared to competitors. While bulls highlight the company's backing by prominent investors, skeptics remain vocal about long development timelines and the risks inherent in fusion-focused microcaps.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius is facing significant volatility and short interest pressure, with traders fiercely debating whether current price levels represent a generational buying opportunity or a deeper correction linked to sector competition and macroeconomic headwinds. Despite the downward pressure, the community remains divided, with long-term investors pointing to strong brand growth and international expansion via Pepsi distribution, while short-sellers highlight concerns over slowing core product momentum and potential market saturation.

Lowe's Companies, Inc. engages in the retail sale of home improvement products. The firm offers products for maintenance, repair, remodeling, home decorating, and property maintenance. It also provides home improvement products in the following categories: appliances, seasonal & outdoor living, lumber, lawn & garden, kitchens & bath, hardware, building materials, millwork, paint, rough plumbing, tools, electrical, flooring, and décor. The company was founded in 1946 and is headquartered in Mooresville, NC.

Lowe`s Cos., Inc.

Lowe's Companies, Inc.

Lowe's shares are trending amid increased investor scrutiny as market participants prepare for upcoming earnings, with community sentiment split between concerns over sluggish DIY demand and optimism regarding potential rebounds from interest rate easing. Traders are heavily monitoring options flow and technical support levels, balancing a cautious macro outlook against strategic acquisitions aimed at expanding the company's Pro-focused market segment.

TOSHI

TOSHI is trending as community members speculate on a potential pivot toward AI utility and ecosystem expansion, citing recent developer updates and strategic partnerships as key catalysts. Discussions remain focused on the potential for a technical breakout, with many holders viewing current market levels as an opportunity to accumulate in anticipation of future growth.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing significant volatility as investors debate whether the recent sharp pullback in the semiconductor sector represents a healthy consolidation or a deeper structural trend reversal. Community sentiment is heavily split, with many traders actively buying the dip based on long-term AI infrastructure growth expectations, while others warn of a potential liquidity trap and further downside risk amid broader market uncertainty.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors gear up for a pivotal data presentation at the upcoming AHNS conference, where the company will showcase its Alpha DaRT technology combined with Keytruda. The community is actively discussing the stock's significant clinical progress, high institutional conviction, and potential for a major rerating as the company transitions toward broader commercialization.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026...

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAmgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income...

Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption

Iovance Biotherapeutics, Inc. (IOVA) a Top Penny Stock to Buy on Amtagvi Strong Adoption...

IBRX Stock Outlook After Q1 Results and a New FDA Review

ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.

ImmunityBio: Anktiva Explained and What Comes Next

IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.

AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than Agenus despite higher valuation.

IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%

Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.

Why Is IOVA Stock Falling Today?

Equity

During the first quarter, Iovance posted a 45% increase in revenue to $71.4 million, which came in below Wall Street’s estimates of $75.6 million, according to Fiscal.ai data.

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of 0.00% and -7.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Alvotech (ALVO) Reports Q1 Loss, Lags Revenue Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of -28.57% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Extremely Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is pacing for a losing week as a semiconductor ($SMH) sell-off has dragged the market lower amid growing doubts about AI spending. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Traders are intensely focused on holding above the key $5 price level to attract institutional buyers and qualify for better margin rates.

Bullish investors are closely watching massive daily volume as they pressure short sellers to cover their positions during a rapid uptrend.

The upcoming earnings call is viewed as a major catalyst for price discovery as the market anticipates potential news on revenue growth.

The community is actively blocking and debating aggressive short-biased accounts as they fight to maintain a positive narrative.

Feed

News

Sentiment

Earnings

Fundamentals

Info

IOVAIovance Biotherapeutics Inc

Fundamentals

Latest IOVA News